Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707080 · ClinicalTrials.gov registry record
Direct Acting Antiviral-Post Authorization Safety Study
A clinical trial, sponsored by Target PharmaSolutions.
- Completed
- Registry status
- 42
- Enrollment target
NCT03707080 is a clinical trial that has completed, run by Target PharmaSolutions. The registered enrollment target is 42 participants.
The verdict
NCT03707080 has completed, sponsored by Target PharmaSolutions.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients following successful HCC treatment interventions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2021-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03707080
The ClinicalTrials.gov registry entry for NCT03707080 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03707080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03707080 about?
NCT03707080 is a clinical study titled "Direct Acting Antiviral-Post Authorization Safety Study". This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepat...
What is the current status of trial NCT03707080?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2018-03-09. Estimated completion is 2021-06-30.
Who is sponsoring clinical trial NCT03707080?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.